Anti-CD-25 antibody
US12129302B2 · kind B2 · utility
0Cited by
25References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2022 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Aug 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Materials and methods for using polypeptides containing fragments and variants of the antibody(ies) or portion(s) thereof that bind CD25 to treat cancer alone or in combination with other anti-neoplastic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.